97 related articles for article (PubMed ID: 27552486)
21. Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis.
Yun SH; Lee WG; Kim YC; Ju ES; Lim BK; Choi JO; Kim DK; Jeon ES
J Infect Dis; 2012 Feb; 205(3):491-7. PubMed ID: 22207647
[TBL] [Abstract][Full Text] [Related]
22. Expression of coxsackievirus and adenovirus receptor (CAR)-Fc fusion protein in Pichia pastoris and characterization of its anti-coxsackievirus activity.
Zhang K; Yu H; Xie W; Xu Z; Zhou S; Huang C; Sheng H; He X; Xiong J; Qian G
J Biotechnol; 2013 Apr; 164(4):461-8. PubMed ID: 23376619
[TBL] [Abstract][Full Text] [Related]
23. Effect of verapamil on acute coxsackievirus B3 murine myocarditis.
Xu Y; Yang YZ; Chen HZ; Jin PY; Guo Q; Zhao WZ; Yang JH; Cai QX; Zhou YC
Chin Med J (Engl); 1992 Oct; 105(10):818-21. PubMed ID: 1337875
[TBL] [Abstract][Full Text] [Related]
24. Soluble coxsackievirus B3 3C protease inhibitor prevents cardiomyopathy in an experimental chronic myocarditis murine model.
Lim BK; Yun SH; Ju ES; Kim BK; Lee YJ; Yoo DK; Kim YC; Jeon ES
Virus Res; 2015 Mar; 199():1-8. PubMed ID: 25485472
[TBL] [Abstract][Full Text] [Related]
25. Disoxaril mutants of Coxsackievirus B1: phenotypic characteristics and analysis of the target VP1 gene.
Nikolova I; Galabov AS; Petkova R; Chakarov S; Atanasov B
Z Naturforsch C J Biosci; 2011; 66(11-12):627-36. PubMed ID: 22351989
[TBL] [Abstract][Full Text] [Related]
26. [The antiviral properties of 4-iodoantipyrine in an experimental enterovirus infection].
Iavorovskaia VE; Gritsenko LN; Petrov SA; Evstropov AN
Vopr Virusol; 1994; 39(4):184-7. PubMed ID: 7998400
[TBL] [Abstract][Full Text] [Related]
27. Cardioprotective effect of NO-metoprolol in murine coxsackievirus B3-induced myocarditis.
Glück B; Dahlke K; Zell R; Krumbholz A; Decker M; Lehmann J; Wutzler P
J Med Virol; 2010 Dec; 82(12):2043-52. PubMed ID: 20981792
[TBL] [Abstract][Full Text] [Related]
28. Protective effects of 20(s)-protopanaxtriol on viral myocarditis infected by coxsackievirus B3.
Wang X; Wang Y; Ren Z; Qian C; Li Y; Wang Q; Zhang Y; Zheng L; Jiang J; Yang C; Wang D; Zhang Y; Fan J; Wang Y
Pathobiology; 2012; 79(6):285-9. PubMed ID: 22688124
[TBL] [Abstract][Full Text] [Related]
29. A murine model of coxsackievirus A16 infection for anti-viral evaluation.
Liu Q; Shi J; Huang X; Liu F; Cai Y; Lan K; Huang Z
Antiviral Res; 2014 May; 105():26-31. PubMed ID: 24583030
[TBL] [Abstract][Full Text] [Related]
30. [Effect of a C-type CpG ODN on CVB3-infected mice].
Yang L; Sun WQ; Wang L; Wang XL; Wan M; Yu YL; Wang LY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Feb; 25(2):115-7. PubMed ID: 19174007
[TBL] [Abstract][Full Text] [Related]
31. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3.
Schmidtke M; Wutzler P; Zieger R; Riabova OB; Makarov VA
Antiviral Res; 2009 Jan; 81(1):56-63. PubMed ID: 18840470
[TBL] [Abstract][Full Text] [Related]
32. Effects of the antiviral WIN 54954 and the immune modulator LS 2616 on cachectin/TNF and gamma-interferon responses during viral heart disease.
Ilbäck NG; Wesslén L; Pauksen K; Stålhandske T; Friman G; Fohlman J
Scand J Infect Dis Suppl; 1993; 88():117-23. PubMed ID: 8390714
[TBL] [Abstract][Full Text] [Related]
33. Expression of short hairpin RNAs against the coxsackievirus B3 exerts potential antiviral effects in Cos-7 cells and in mice.
Kim JY; Chung SK; Hwang HY; Kim H; Kim JH; Nam JH; Park SI
Virus Res; 2007 Apr; 125(1):9-13. PubMed ID: 17222937
[TBL] [Abstract][Full Text] [Related]
34. The in vitro and in vivo antiviral effects of salidroside from Rhodiola rosea L. against coxsackievirus B3.
Wang H; Ding Y; Zhou J; Sun X; Wang S
Phytomedicine; 2009 Mar; 16(2-3):146-55. PubMed ID: 18818064
[TBL] [Abstract][Full Text] [Related]
35. Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3.
Werk D; Pinkert S; Heim A; Zeichhardt H; Grunert HP; Poller W; Erdmann VA; Fechner H; Kurreck J
Antiviral Res; 2009 Sep; 83(3):298-306. PubMed ID: 19591879
[TBL] [Abstract][Full Text] [Related]
36. Detection of viral RNA in experimental coxsackievirus B3 myocarditis of mice using the polymerase chain reaction.
Okada I; Matsumori A; Kyu B
Int J Exp Pathol; 1992 Dec; 73(6):721-31. PubMed ID: 1337265
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
Zhou L; He X; Gao B; Xiong S
J Virol; 2015 Oct; 89(20):10512-23. PubMed ID: 26269170
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
[TBL] [Abstract][Full Text] [Related]
39. [Inhibitory effect of Chinese herbal medicine Xin-Kang oral liquid on replication of CVB3 RNA in Coxsackievirus B3 infected mice].
Wan SJ; Yang F; Huang XZ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):238-40. PubMed ID: 17971932
[TBL] [Abstract][Full Text] [Related]
40. Prevention of death in mice infected with coxsackievirus A16 using guanidine HCl mixed with substituted benzimidazoles.
Herrmann EC; Herrmann JA; Delong DC
Antiviral Res; 1982 Dec; 2(6):339-46. PubMed ID: 6299189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
